SCHEMBL6491865

SCHEMBL6491865

Cc1ccc(S(=O)(=O)NC(=O)c2ccc3nc(C)n(Cc4cc([N+](=O)[O-])c(Cl)cc4Cl)c3n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.43
PTGS1 P23219 2/20 0.43
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
EGFR P00533 4/20 0.40
ERBB2 P04626 2/20 0.40
FLT1 P17948 3/20 0.38
FLT4 P35916 3/20 0.38
KDR P35968 3/20 0.38
MCL1 Q07820 1/20 0.37
ALKBH2 Q6NS38 1/20 0.37
ALKBH5 Q6P6C2 1/20 0.37
ALKBH3 Q96Q83 1/20 0.37
FTO Q9C0B1 1/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36
PPARG P37231 1/20 0.36
GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491433 0.86 PTGS2 (0.43) PTGS2PTGS1MAPTEGFRFLT1
SCHEMBL6299390 0.86 FLT1 (0.50) PTGS2PTGS1LMNAEGFRERBB2
SCHEMBL6491775 0.85 PPARG (0.54) LMNAMAPTPPARG
SCHEMBL6491759 0.85 PTGS2 (0.43) PTGS2PTGS1MAPTEGFRFLT1
SCHEMBL6491743 0.84 PTGS2 (0.44) PTGS2PTGS1MAPTEGFRERBB2
SCHEMBL6134163 0.84 PTGS2 (0.43) PTGS2PTGS1MAPTEGFRERBB2
SCHEMBL6493091 0.84 PTGS2 (0.43) PTGS2PTGS1LMNAMAPTEGFR
SCHEMBL7837434 0.84 KMT2A (0.41) LMNAMAPTMEN1ALDH1A1KMT2A
SCHEMBL6491706 0.84 KMT2A (0.41) LMNAMAPTMEN1ALDH1A1KMT2A
SCHEMBL6298863 0.83 MEN1 (0.45) PTGS2PTGS1MAPTEGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US claimed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US claimed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP claimed
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A PTGS2 140/4885PTGS1 86/4885LMNA 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.